Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning within health technology is shifting, and why more and more biotech firms are choosing to IPO in Hong Kong.
When it comes to a pandemic like COVID-19, diagnostics is the first priority. You first have to find out where the disease is before you can respond to it. Vaccines and therapeutics will take a long time to materialize
